Brief: CytomX Therapeutics Announces Milestone Achievement In PROBODY® T-Cell Engaging Bispecific Collaboration With Astellas
18/03/2024 13:37
March 18 (Reuters) - CytomX Therapeutics Inc CTMX.O :
* CYTOMX THERAPEUTICS ANNOUNCES MILESTONE ACHIEVEMENT IN
PROBODY® T-CELL ENGAGING BISPECIFIC (TCB) COLLABORATION WITH
ASTELLAS
* CYTOMX THERAPEUTICS - INITIATION OF GLP TOXICOLOGY STUDY
FOR
FIRST CLINICAL CANDIDATE IN COLLABORATION TRIGGERS A $5 MILLION
MILESTONE PAYMENT TO CYTOMX
* CYTOMX THERAPEUTICS INC - PROGRAM IS ONE OF SEVERAL
ONGOING
COLLABORATION PROJECTS IN BROAD CYTOMX-ASTELLAS ALLIANCE ON
T-CELL ENGAGING BISPECIFICS
* CYTOMX THERAPEUTICS INC - CYTOMX RETAINS OPTION FOR US
CO-COMMERCIALIZATION AND ECONOMIC RIGHTS FOR CERTAIN PROGRAMS
Source text for Eikon: ID:nGNX2B3p8Y
Further company coverage: CTMX.O
Recent news on CytomX Therapeutics
See all newsCytomX Q2 revenue misses, partly hurt by lower research activities in the Astellas collaboration
CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Cytomx Therapeutics Announces Appointment Of Charles Fuchs, M.D., M.P.H., To The Board Of Directors
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway